Slenyto 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0027 
Minor change in labelling or package leaflet not 
16/02/2024 
connected with the SPC (Art. 61.3 Notification) 
N/0024 
Minor change in labelling or package leaflet not 
24/11/2023 
connected with the SPC (Art. 61.3 Notification) 
PL 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
IB/0022/G 
This was an application for a group of variations. 
15/08/2023 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
IAIN/0023 
A.5.a - Administrative change - Change in the name 
13/07/2023 
and/or address of a manufacturer/importer 
responsible for batch release 
Annex II and 
PL 
R/0021 
Renewal of the marketing authorisation. 
30/03/2023 
05/06/2023 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
PL 
Slenyto in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IA/0020/G 
This was an application for a group of variations. 
25/10/2022 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/1963/
Periodic Safety Update EU Single assessment - 
10/06/2021 
n/a 
PRAC Recommendation - maintenance 
202009 
melatonin 
II/0017 
The update of the product information to reflect 
18/02/2021 
02/06/2022 
SmPC, Annex 
The Product Information is updated to reflect relevant 
information from children treated with Circadin 
during the French RTU program and the known 
safety profile of Circadin authorised for adults. 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
II and PL 
information from paediatric French program and the known 
safety profile of Circadin in adults. 
For more information, please refer to the Summary of 
Product Characteristics. 
IB/0018 
B.I.e.5.b - Implementation of changes foreseen in an 
03/11/2020 
n/a 
approved change management protocol - Requires 
further supportive data 
IA/0016 
B.II.e.1.b.3 - Change in immediate packaging of the 
26/05/2020 
21/04/2021 
SmPC, 
finished product - Change in type/addition of a new 
container - Deletion of an immediate packaging 
container without a complete deletion of a strength 
or pharmaceutical form 
Labelling and 
PL 
IB/0015 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
13/03/2020 
21/04/2021 
SmPC 
storage conditions of the finished product - Other 
variation 
IB/0014 
B.I.e.4.b - Changes to an approved change 
13/03/2020 
n/a 
management protocol - Minor changes that do not 
change the strategy defined in the protocol 
II/0010 
C.I.13 - Other variations not specifically covered 
31/10/2019 
n/a 
elsewhere in this Annex which involve the submission 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of studies to the competent authority 
IB/0012 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
22/08/2019 
24/02/2020 
SmPC 
storage conditions of the finished product - Other 
variation 
N/0011 
Minor change in labelling or package leaflet not 
11/06/2019 
24/02/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0009/G 
This was an application for a group of variations. 
03/06/2019 
n/a 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.b.4.z - Change in the batch size (including batch 
size ranges) of the finished product - Other variation 
IB/0008/G 
This was an application for a group of variations. 
21/05/2019 
n/a 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
packaging, for non-sterile medicinal products 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.4.z - Change in the batch size (including batch 
size ranges) of the finished product - Other variation 
N/0007 
Minor change in labelling or package leaflet not 
29/04/2019 
24/02/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
T/0004 
Transfer of Marketing Authorisation 
04/01/2019 
11/03/2019 
SmPC, 
Labelling and 
PL 
IB/0006 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
19/02/2019 
24/02/2020 
SmPC 
storage conditions of the finished product - Other 
variation 
IB/0005 
C.I.z - Changes (Safety/Efficacy) of Human and 
04/01/2019 
11/03/2019 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0003 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
04/01/2019 
11/03/2019 
SmPC 
storage conditions of the finished product - Other 
variation 
IB/0002 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
16/11/2018 
11/03/2019 
SmPC 
storage conditions of the finished product - Other 
variation 
IB/0001 
B.II.e.5.a.2 - Change in pack size of the finished 
14/11/2018 
11/03/2019 
SmPC, 
product - Change in the number of units (e.g. 
Labelling and 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change outside 
PL 
the range of the currently approved pack sizes 
Page 6/6 
 
 
 
 
 
 
 
